We believe are at a breakthrough moment in Research & Development (R&D) in neurodegeneration, driven by growing evidence of overarching biological processes that drive neurodegenerative disorders.
Our ambition at Johnson & Johnson is to become a leader in neurodegeneration. We are working to develop innovations for a diverse range of patients, from large, clinically diverse populations.
This work begins with R&D, where we have potentially transformational early science in Alzheimer’s disease (AD). We are utilizing plasma biomarkers in our trials to detect central amyloid positivity and tau status.